You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company said it is using the technology for synthetic biology, diagnosis of inherited genetic diseases, liquid biopsy, and infectious disease detection.
Single-cell analysis, next-generation sequencing, and synthetic DNA have all been crucial to efforts to find antibodies that could neutralize SARS-CoV-2.
The researchers used a yeast-based synthetic genomics platform to engineer and resurrect chemically synthesized clones of the SARS-CoV-2 virus in only a week.
The company — formerly called Expedeon — recently divested its proteomics and immunology businesses in order to focus on the manufacture and supply of synthetic DNA.
The method can be used with isothermal amplification and paper-based readouts to detect infectious disease drug resistance in low-resource areas.
The DNA synthesis company priced shares of common stock at $28 and increased the expected proceeds from its stock offering to $130 million.
The offering of common stock will be the second for Twist this year and the third since the company made its initial public offering in October 2018.
On a conference call to discuss the firm's fiscal Q1 financial results, Twist executives detailed the firm's vision for near- and long-term growth.
A hearing scheduled for Friday, part of a lawsuit filed by Agilent was cancelled, leading to speculation the sides were close to a settlement.
Illumina, Twist Bioscience, and DNA Script are among the private sector collaborators of the groups receiving funds to develop technology platforms.
The European firms will collaborate to scale up manufacturing of proprietary silicon chips used in Evonetix's benchtop DNA synthesis platform.
Researchers in academia and industry are showing interest in the scale offered by Inscripta's Onyx platform for genome editing, launched in October.
The firm said it plans to sign between five and 10 additional biopharma collaborations in fiscal year 2020, some with milestone and royalty payment structures.
The firm reported full year revenues of $54.4 million and fiscal Q4 revenues of $15.7 million, beating the consensus Wall Street estimates for both.
Two new grants are helping the company develop its SHERLOCK and INSPECTR technologies as the basis for creating innovative diagnostics.
Last week's SynBioBeta conference was indicative of the high degree of interest in the synthetic bio space from omics research tool vendors.
Ginkgo plans to strategically partner with leading companies in mature markets to create synthetic biology-based spinouts, something it has already done in ag-bio.
The San Diego-based DNA synthesis firm this week announced $12.2 million in Series A funding, but has plans to expand the round.
Ginkgo will acquire Beacon optofluidic platforms from Berkeley Lights and incorporate them into its automated genetic engineering foundries.
The Boston-based synthetic biology firm said it will use the funds to grow its cell programing platform, which it will make available to startups.
The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.
According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.